These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 19302906)

  • 41. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours.
    Weigang-Köhler K; Vetter A; Thyroff-Friesinger U
    Onkologie; 2009 Apr; 32(4):168-74. PubMed ID: 19372711
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does price reveal poor-quality drugs? Evidence from 17 countries.
    Bate R; Jin GZ; Mathur A
    J Health Econ; 2011 Dec; 30(6):1150-63. PubMed ID: 21917346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Update on reintroduction of epoetin in a patient with pure red call aplasia.
    Campbell N; Krishnakumar S; Matijevic A; Almond M
    Nephrol Dial Transplant; 2008 Oct; 23(10):3365. PubMed ID: 18567693
    [No Abstract]   [Full Text] [Related]  

  • 44. Feasibility of a multiplex flow cytometric bead immunoassay for detection of anti-epoetin alfa antibodies.
    Ferbas J; Thomas J; Hodgson J; Gaur A; Casadevall N; Swanson SJ
    Clin Vaccine Immunol; 2007 Sep; 14(9):1165-72. PubMed ID: 17634512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application.
    Okano M; Sato M; Kaneko E; Kageyama S
    Drug Test Anal; 2011; 3(11-12):798-805. PubMed ID: 22012825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin.
    Ryan MH; Heavner GA; Brigham-Burke M; McMahon F; Shanahan MF; Gunturi SR; Sharma B; Farrell FX
    Int Immunopharmacol; 2006 Apr; 6(4):647-55. PubMed ID: 16504928
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody-mediated pure red cell aplasia (PRCA): ensuring future progress by collecting data from a registry.
    Aljama P; Carracedo J; Madueño JA; Ramirez R; Martin-Malo A; Martin de Francisco AL
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv27-30. PubMed ID: 15827055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights.
    Macdougall IC; Roger SD; de Francisco A; Goldsmith DJ; Schellekens H; Ebbers H; Jelkmann W; London G; Casadevall N; Hörl WH; Kemeny DM; Pollock C
    Kidney Int; 2012 Apr; 81(8):727-32. PubMed ID: 22336988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quality of cold storage drugs transportation and delivery to Thai hospitals.
    Sooksriwong CO; Bussaparoek W
    J Med Assoc Thai; 2009 Dec; 92(12):1681-5. PubMed ID: 20043573
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical safety of biosimilar recombinant human erythropoietins.
    Abraham I; MacDonald K
    Expert Opin Drug Saf; 2012 Sep; 11(5):819-40. PubMed ID: 22880621
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epoetins: differences and their relevance to immunogenicity.
    Haselbeck A
    Curr Med Res Opin; 2003; 19(5):430-2. PubMed ID: 13678480
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epoetin-induced autoimmune pure red cell aplasia.
    Casadevall N
    Hematol J; 2004; 5 Suppl 3():S104-9. PubMed ID: 15190289
    [No Abstract]   [Full Text] [Related]  

  • 53. [Pure red cell aplasia and antibodies against erythropoietin. Doubts still remain].
    Peces R
    Nefrologia; 2003; 23(4):295-6, 297. PubMed ID: 14558327
    [No Abstract]   [Full Text] [Related]  

  • 54. Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?
    Hermeling S; Schellekens H; Crommelin DJ; Jiskoot W
    Pharm Res; 2003 Dec; 20(12):1903-7. PubMed ID: 14725351
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protein isolated from biopharmaceutical formulations cannot be used for comparative studies: Follow-up to "a case study using Epoetin Alfa from Epogen and EPREX".
    Heavner GA; Arakawa T; Philo JS; Calmann MA; Labrenz S
    J Pharm Sci; 2007 Dec; 96(12):3214-25. PubMed ID: 17721976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Are there counterfeit medicines in Croatia?].
    Tomić S; Milcić N; Sokolić M; Sucić AF; Martinac AI
    Lijec Vjesn; 2010; 132(3-4):81-6. PubMed ID: 20540433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties.
    Storring PL; Tiplady RJ; Gaines Das RE; Stenning BE; Lamikanra A; Rafferty B; Lee J
    Br J Haematol; 1998 Jan; 100(1):79-89. PubMed ID: 9450795
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Stability of reconstituted fluconazole oral suspension in plastic bottles and oral syringes.
    Dentinger PJ; Swenson CF
    Ann Pharmacother; 2009 Mar; 43(3):485-9. PubMed ID: 19208778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lesson learned from Eprex-associated pure red cell aplasia.
    Schellekens H
    Kidney Blood Press Res; 2007; 30 Suppl 1():9-12. PubMed ID: 17726337
    [No Abstract]   [Full Text] [Related]  

  • 60. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis.
    Bate R; Jensen P; Hess K; Mooney L; Milligan J
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):308-11. PubMed ID: 23321423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.